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ABSTRACT: Nicotine addiction remains the 
leading cause of death and disease in developed and 
developing nations and a major cause of mortality 
around the world. Currently, nicotine replacement 
therapies (NRTs), bupropion, and varenicline are 
approved by the regulatory agencies as first-line 
treatments for nicotine addiction. Emerging evidence 
indicates that varenicline and bupropion have 
some therapeutic limitations for treating nicotine 
addiction with oral route of administration. Thus, 
continued investigation of innovative drug delivery 
for nicotine addiction remains a critical priority. 
This review will discuss some novel strategies and 
future directions for pulmonary drug delivery, 
an emerging route of administration for smoking 
cessation. It is anticipated that the advancement of 
knowledge on pulmonary drug delivery will provide 
better management for nicotine addiction and other 
addictive disorders.
Keywords: Nicotine addiction, bupropion, varenicline, 
nicotinic receptor, pulmonary drug delivery, dry powder 
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1. Introduction
Tobacco smoking and nicotine addiction is a growing 
public health problem in the developing and developed 
world. The World Health Organization (WHO) 
estimates that about 30% of the adult male global 
population smokes (1). It is estimated that each year 
tobacco smoking accounts for about 3 million deaths 
worldwide. Unless the current trends are reversed, by 
the year 2030, this figure will be increased to 10 million 
deaths every year. Seventy percent of these deaths are 
predicted to be in developing nations. In the USA alone, 
tobacco smoking causes 440,000 deaths annually (2). 
Approximately, 50% of long-term tobacco smokers 
die prematurely from adverse effects of smoking, 
including cancer, cardiovascular disease, lung disease 
or other illness (3). The risk of tobacco smoking 
can be reduced significantly by smoking cessation 
with multiple strategies including pharmacotherapy. 
Current pharmacotherapies (Table 1) include nicotine 
replacement therapy (NRT) in the form of gum, 
transdermal patch, sublingual tablet, nasal spray, and 
vapor inhaler formulations; however, each therapy has 
its advantages as well as some significant drawbacks 
(details in the section 5.1.). There are two non-nicotine 
based medications which have been approved by the 
US Food and Drug Administration which are bupropion 
(Zyban) and varenicline (Chantix) (4-6). Recent data 
suggest that varenicline and bupropion have some 
therapeutic limitations or adverse effects for treating 
nicotine addiction with current delivery system. Like 
other brain disorders (Table 2), continued investigation 
of innovative drug delivery for nicotine dependence 
remains a critical priority. In this review, we will discuss 
novel strategies and future directions for smoking 
cessation using a suitable inhaler for deep lung delivery 
of nicotine, an emerging route of drug administration. 
The currently available nicotine inhaler delivers nicotine 
into the mouth for buccal absorption and there is no 
ideal inhaler to deliver nicotine into the deep lung. The 
pulmonary route of nicotine delivery would be expected 
to mimic the effects of tobacco smoking and would 
significantly reduce cravings and withdrawal symptoms. 
It is anticipated that the advancement of knowledge on 
pulmonary drug delivery will provide novel therapeutic 
formulations for better management of nicotine addicted 
population. Improvement of nicotine addiction treatment 
depends on the novel pharmacotherapeutic approaches, 
including new drugs or new formulation of current drugs 
and/or novel delivery technique, like deep lung delivery, 
which is discussed in the following sections.
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2. Pulmonary delivery technology
Aerosol delivery of drugs, formulated as liquid 
solutions, suspensions, emulsions, or micronized dry 
powders, are aerosolized via some commonly used 
different types of delivery devices i.e., nebulizers, 
metered dose inhaler (MDI), and dry powder inhaler 
(DPI). Nebulizers deliver large volumes of drug 
solutions or suspensions and are used for those drugs 
which are difficult to be formulated into pressurized 
metered dose inhalers (pMDIs) or DPIs. Nebulizers are 
suitable for drugs with high dose and little patient co-
ordination or skill; however, treatment using nebulizer 
is time consuming and less efficient, resulting in the 
waste of active medicaments. They are not portable 
devices and have been limited to the treatment of 
hospitalized patients only.
 Metered dose inhalers/pMDIs are the most 
commonly used delivery devices (Figure 1), which 
deliver drug. In this delivery method, drug is either 
dissolved or suspended in liquefied propellents. The 
propellents used in pMDI formulations are liquefied 
gases of chloroflurocarbons (CFC), which are not 
environmental friendly. This is the reason why 
currently hydrofluoroalkanes (HFAs), which have no 
remarkable effects on the ozone layers, are used in the 
formulation for MDIs. On spraying, drug formulation 
with propellants is expelled and aerosolized (Figure 1). 
Although pMDIs are widely used in respiratory drug 
delivery, some problems have been associated with 
these devices, including the need for coordination of 
inspiratory inhalation with valve actuation and the use of 
a propellant, which has possible adverse effects on the 
stratospheric ozone layer. 
 In addition, pMDIs have some other disadvantages 
such as oropharyngeal deposition of drugs. On actuation, 
the particles aerosolized from the MDIs have a high 
velocity, which exceeds the patients' inspiratory force, 
therefore, a large number of particles deposit onto the 
oropharyngeal areas. Thus a small fraction of drug 
deposits into the patients lungs due to a lack of co-
ordination between actuation and inhalation (7). To 
overcome this difficulty several inhalation aids like 
spacers incorporated with MDIs have been developed 
(8) to improve the delivery; however, bacterial 
contamination of spacer devices are very common if the 
devices are not cleaned and dried appropriately (9). 
 Dry powder inhalation formulations contain the 
drug in a powder form and the drug particles (< 5 μm) 
are blended with a suitable large carrier (i.e., lactose) 
to improve flow properties and dose uniformity (10) 
and drug powders are delivered into the deep lung via 
DPI devices (Figure 2). Powder de-agglomeration and 
aerosolisation from these formulations are achieved by 
the mechanical force provided by the device and patient's 
inspiratory airflow, which needs to be sufficient to create 
an aerosol containing respirable drug particles for lung 
deposition. Good flow properties of the formulation are 
necessary to ensure accurate dose metering of the drug. 
Advantages of DPI over other inhaler systems (pMDIs) 
are independence of breathing co-ordination with dose 
actuation, the absence of propellants, low innate initial 
velocity of particles (reducing inertial impaction at the 
back of the throat), and solid state drug stability. Drug 
dispersion from the powder formulation can be enhanced 
by the addition of fine excipients in the formulation 
(11,12). Drug particle size and powder formulation, 
breathing patterns, and complex physiology of respiratory 
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Table 2. Drugs administered as aerosols against smoking cessation and other neurological diseases
Active drugs
Nicotine
Nicotine
Nicotine
Nicotrol®, Nicorette® (Nicotine)
Dihydroergotamine mesylate
Ergotamine tartrate
Detorelix
Dopamine D-1 agonist, ABT-431
L-Dopa
Dopamine agonist
Indication
Smoking cessation
Smoking cessation 
Smoking cessation
Smoking cessation
Migraine, Vascular cephalgia
Migraine, Vascular cephalgia
Migraine, Vascular cephalgia
Parkinson's disease
Parkinson's disease
Parkinson's disease
Formulation
Aqueous solution
Suspension
Micronized powder
Nicotine cartridge/Liquid
HFA 134a based suspension 
Suspension
Suspension of liposomal drugs
HFA based suspension
Micronized powder
Suspension in propellant and poloxamer
Delivery system
MDI (AERx Essence®)
MDI
DPI
DPI & MDI
MDI
Unavailable
Intratracheal (i.t.) instillation 
MDI (AERx)
Alkermes AIR/DPI
MDI
References
(72,73)
(70,71,83)
(67)
(64,68)
(84)
(50)
(85)
(86,87)
(52,88)
(89)
MDI: metered dose inhaler; HFC is hydrofluoro alkane; AERx is a DPI device that deliver aerosolized drugs from a dosage form that consists of liquid 
drug formulation. 
Table 1. Currently approved medications for smoking cessation (4, 57)
Delivery methods
Oral, nasal, skin, nicotine cartridges in an inhaler, pMDI
Oral
Oral
Pharmacotherapy
NRT*
Bupropion (Zyban®)
Varencline (Chantix®)
Common side effects
Skin reaction, insomnia, irritation of mouth and throat
Insomnia, dry mouth, suicide ideation
Headache, mood changes, insomnia, constipation, suicide ideation
* NRT: nicotine replacement therapy.
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and breathing patterns of the patients (15-17). Inertial 
impaction and sedimentation are the most important 
for large particle deposition (1 μm < MMAD < 10 μm). 
Large particles (> 5 μm) with high velocity (due to higher 
mass) are mainly deposited by impaction (18). Particles 
of smaller size (0.5-3.0 μm), which have tendency to 
escape from deposition by inertial impaction, may be 
deposited by sedimentation. Deposition of small particles 
by sedimentation mainly occurs in the smaller airways 
and alveolar regions and increased sedimentation is 
observed during breath-holding or slow steady breathing 
(18). Deposition of particles less than 0.5 μm occurs in 
the lower airway of lungs by diffusion due to Brownian 
movement. Generally, the deposition of particles larger 
than 1.0 μm is dominated by inertial impaction and 
particles smaller than 0.1 μm are deposited by diffusion. 
Both sedimentation and diffusion are important for 
the particle size ranging between 0.1-1.0 μm (19). The 
maximum pulmonary deposition of particles of 1.5-2.5 
μm and 2.5-4 μm diameters occurred with and without 
breath holding, respectively. However, rapid breathing 
showed maximum deposition of particles between 1.5-2 
μm in the tracheobronchial region with breath holding 
and particles between 2-3 μm deposited in the pulmonary 
tract are major factors affecting delivery of drugs into 
the deep lung. DPIs are highly portable, breath activated, 
and relatively less expensive. Since drugs are kept in 
solid state in DPIs, they exhibit high physicochemical 
stability of drugs particularly proteins and peptides. In 
DPI formulation the device is an important factor in 
achieving adequate delivery of inhaled drug to lungs. 
The device must provide an environment where the drug 
can maintain its physicochemical stability and produce 
reproducible drug dosing.
 On inhalation, drugs are dispersed and delivered into 
deep lungs. To achieve a desired therapeutic effect from 
aerosols, an adequate amount of drug must reach the 
alveolar sacs of the respiratory airways. The dynamic 
behavior of aerosol particles is governed by the laws 
of aerosol kinetics (13). The dominant mechanisms of 
depositing aerosol particles into the respiratory tract 
include inertial impaction, sedimentation (gravitational 
deposition), Brownian diffusion, interception, and 
electrostatic precipitation (14). The distribution of 
the inhaled drug particles in the lung depends on 
the characteristics of the inhaled particles, such as 
drug particle diameter, mass, shape, density and 
hygroscopicity, the physiology of the respiratory tract, 
Figure 1. Schematic diagram of aerosol delivery of drugs from pMDI. Modified form Dalby et al. (94).
Figure 2. Schematic diagram of the pulmonary delivery of drugs from DPI formulation. The formulation consists of 
micronized drugs adhered on the surface of large carrier particles. Drug particles detached from the surface of large carriers and 
deposits into the patients airways by inhalation.
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region without breath holding (15). Therefore, slow 
inhalation is desirable to obtain maximum deposition of 
aerosol particles in the lower airways of lung. Although 
particles less than 1 μm have challenging dispersion 
behavior due to the strength of the inter-particle forces, 
inhaled nanoparticles or nanoagglomerates of various 
drugs showed better dispersion (20-24), rapid absorption 
(25), and avoidance of mucociliary clearance (26). 
Recently, a formulation containing carrier lactose and 
salbutamol sulphate nanoparticles, which demonstrated 
a 2- to 3-fold increase in total lung deposition compared 
to a formulation containing the same drug as micronized 
form (20) has been reported.
 Electrostatic charges may be generated in a DPI on 
particles of an aerosol and a charged particle may induce 
an image charge of opposite polarity on the airway 
walls during inhalation. This image charge attracts the 
particle which is subsequently deposited by electrostatic 
precipitation (18,27). Only fibrous particles are believed 
to be deposited by this mechanism, therefore, this 
mechanism may not be significant for DPI formulations. 
3. Pulmonary delivery of various drugs
Currently, local delivery of medicaments to the alveoli of 
lungs from both DPIs and pMDIs are mainly used for the 
treatment of lung disorders including asthma and chronic 
obstructive pulmonary disorders (COPD) and a limited 
number of therapeutic compounds such as β-adrenoceptor 
agonist, muscarinic agonist, corticosteroids, and mast cell 
stabilizers are available. Recently certain combinations of 
drugs are also formulated due to a synergistic therapeutic 
benefit. Zanamavir, an antiviral agent has been introduced 
in the market as an aerosol product for the treatment 
of influenza (28). Aerosol delivery of recombinant 
human deoxyribonuclease (rhDNase) and tobramycin 
are available as nebulizer for the treatment of cystic 
fibrosis (28,29). The very first approved aerosol delivery 
of insulin as DPI formulation (Exubera®, Pfizer) was 
introduced in the market, however, the production has 
been discontinued from market because the sales of this 
product were disappointing as the product failed to gain 
acceptance of patients and physicians. The manufacturer 
failed to demonstrate the clinical benefits of the inhaled 
insulin over the currently available self-injection insulin 
products to the doctors and patients. Although the DPI 
product is stable (compared to the liquid injectable 
product) and easy to use; however, due to the higher 
cost of Exubera®, clumsy design of the device and poor 
marketing are also responsible for this breakdown.
 Using DPI technique respiratory delivery of other 
potent drugs or other agents, such as hormone (30), 
antibiotics (31,32), drugs for Parkinson's disease 
(33), gene delivery (34,35), vaccine delivery (36-38), 
antituberculosis (39,40), antihypertensive nifedipine (21), 
anticoagulant heparin (41), drugs for sexual dysfunction 
(42), opioids (fentanyl) for cancer pain (43-45), and 
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atropine sulphate nanoparticle as an antidote for 
organophosphorus poisoning with better bioavailability 
have been reported (46). The inhaled dry powders of 
levodopa showed to produce a therapeutic effect within 
10 min of administration for the treatment of Parkinson's 
disease (47). Using a mouse model, deep lung delivery 
of poorly water soluble drug, ibuprofen nanoparticle 
showed 3-5 orders of magnitude less dose than that 
required for oral administration of the drug to achieve the 
same analgesic effect (48). Deep lung delivery of various 
drugs has been investigated and the pulmonary route has 
been found to be more effective compared to those of 
other routes. Aerosol delivery offers the greatest potential 
to delivery drugs into the lower airway of lungs of a wide 
range of molecules for systemic diseases.
4. Pharmacokinetics of some inhaled drugs
Very little is known about the pharmacokinetics of inhaled 
drugs. Recently, the bioavailability of levonorgestrel after 
pulmonary and oral administration has been investigated 
and pulmonary delivery of liposome encapsulated 
levonorgestrel produced prolonged effective concentration 
of the drug in the plasma over a period of 16-60 h 
with reduced side effects compared to that of orally 
administered drug (49). Higher plasma concentration 
of ergotamine tartrate was found when delivered via 
pulmonary route compared to that of orally administered 
tablet (50). This study revealed the superiority of inhaled 
route to the oral route of drug delivery. In another study, 
inhaled L-dopa produced at least 2-fold fewer doses 
compared to that of oral dose (51). Using a rat model, lung 
delivery of L-dopa dry powder formulation, developed by 
Alkerme's Advanced Inhalation Research (AIR), showed 
rapid and higher plasma levels (Cmax, 4.8 ± 1.10 mg/mL in 
2 min) compared to that of oral administration where the 
drug produced delayed and lower plasma level (Cmax, 1.8 
± 0.40 mg/mL) in 30 min (52).
 Deep lung delivery of Ergotamine tartrate (ET) via an 
inhaler (Medihaler®) produced 9-fold higher peak plasma 
concentration (Cmax, 1,109 pg/mL at 4 min) compared 
to that of sublingual ET formulation (Cmax, 134.0 pg/mL 
at 37 min) (53). Inhaled testosterone in postmenopausal 
women delivered by AREx (a novel handheld aerosol 
delivery system) produced a dose dependent increase 
in plasma drug concentration (54). After administering 
the maximum dose of 3.0 mg, plasma concentration 
(Cmax) of free testosterone was increased from 0.6 
nmol/L to a maximum level of 62.6 nmol/L achieved 
within 1-2 min after dosing. The authors demonstrated 
that the administration of inhaled testosterone was 
safe and no adverse effects related to the treatment 
occurred. Inhalation route can be an alternative route 
with safety profile to consider for many therapeutic 
agents (55). Thus the lung delivery of drugs has a lot of 
potential in managing various diseases with excellent 
pharmacokinetic profiles.
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5. Medications for smoking cessation
5.1. Nicotine replacement therapy 
Nicotine replacement therapy (NRT) may facilitate 
smoking cessation in several ways. The primary action 
is believed to be the relief of craving and withdrawal 
symptoms when a person stops tobacco use (56). 
The second critical effect of NRT is being positive 
reinforcement. The third possible mechanism of benefit 
has been suggested to be the potential for nicotine 
based medications to desensitize brain nicotinic 
acetylcholine receptors (nAChRs). A desensitized state 
of nAChRs such as alpha4beta2 subtype and/or other 
subtypes may cause in reduced receptor responsiveness 
to endogenously released acetylcholine which may 
be relevant to general mood stabilizing effect (57). 
Currently, NRT is available in 5 different formulations 
with different pharmacokinetic profiles, i.e., chewing 
gum, lozenges, sublingual tablets, transdermal patch, 
and/or nasal spray inhale. The gum is available in two 
doses (2 or 4 mg) and the amount of drug absorbed 
from nicotine gum is much lower (~50%) than nicotine 
content in the formulation. With regards to the lozenges 
chewing is not required but like gum, nicotine from 
this preparation is absorbed very slowly through the 
buccal mucosa. A significant amount of nicotine is 
swallowed when using sublingual tablets, gum or 
lozenges and undergoes hepatic first pass metabolism 
and thus reduced bioavailability (20-45%) (58,59). The 
transdermal patch is much easier to use; however, the 
rate of nicotine delivery from this formulation is very 
slow and has an initial lag time of about 1 h before 
nicotine appears in the blood stream and a very slow 
rise (2-6 h) (60). Nicotine absorption from sublingual 
tablets are somewhat higher than that of gum; however, 
efficacy rates appeared to be consistent with gum and 
lozenge preparation (61). Absorption of nicotine from 
capsules or solutions is not promising and peak plasma 
concentrations are achieved in about 1 h after oral 
administration (59,62). Nicotine is ionized at low pH 
(stomach) and thus poorly absorbed from the stomach 
but it is well absorbed from intestine due to alkaline pH. 
The pharmacokinetics of currently available nicotine 
dosage forms are presented in Table 3, which indicates 
that the absorption of nicotine from orally administered 
formulations is slower and peak plasma concentrations 
are gradual compared to that of smoking. No significant 
difference in efficacy has been shown between 
formulations (3). Nicotine absorption from nasal 
spray is very rapid (Cmax 8.6-10.5 ng/mL at 2.5-5 min) 
(63) compared to that of gum; however, it has some 
unavoidable drawbacks like burning nose and throat, 
watery eyes, runny nose, sneezing, and coughing (64), 
which limit its application in smoking cessation. The 
nicotine vapor inhaler (inhaled by mouth) containing 
nicotine cartridge (10 mg each) deliver nicotine more 
into the oral cavity, stomach and very little into lungs 
(65). This is not a real inhaler that delivers drug into 
the deep lungs for better absorption. In addition, the 
nicotine delivery from this type of inhaler is temperature 
dependent (to vaporize the nicotine) and the inhaler is 
required to be kept warm before inhalation. From the 
above discussion, it is evident that each of the above 
mentioned nicotine based therapy has its advantages as 
well as some unavoidable limitations.
 Although these products are alternatives of the 
nicotine associated with tobacco consumption, none 
of these found to produce rapid absorption and quick 
onset of action that can be achieved with cigarette. It is 
assumed that these products do not show the ability to 
effectively relief the craving for cigarettes associated 
with nicotine withdrawal. Therefore, this intense craving 
drives smokers back to cigarettes. New delivery method 
such as pulmonary drug delivery may enhance the 
efficacy of some NRT formulations. The pulmonary 
route is known as one of the efficient methods of 
delivering drugs to the body due to large surface area of 
the pulmonary alveoli, small airways, and dissolution 
of nicotine products in the fluid of pH 7.4 in the lungs 
facilitates transfer across membrane. A unique inhaler 
(DPI or MDI) would deliver nicotine to the lung in a 
manner comparable to nicotine intake through smoking. 
It is anticipated that this new method like lung delivery 
of nicotine would reduce background cravings and 
withdrawal symptoms for rapid relief of cravings 
(57,66). Thus pulmonary drug delivery technology 
may revolutionize the effective treatment by right NRT 
formulations and the following section is dedicated to 
demonstrate the current status and future direction of 
developing inhalable nicotine formulation. 
Table 3. Pharmacokinetics (average values) of different 
dosage forms of Nicotine products
Dosage forms and administration
Smoking
      1.1 mg/cigarette
      0.9 mg/cigarette
MDI 
      50 μg /puff (0.5 mg dose)
      100 μg /puff (1.0 mg dose)
Vapor Inhaler (10 mg cartridge)
Nasal spray (2.0 mg)
Nicotine vapor inhaler (1.1mg)
Nicotine Gum (2.0 mg)
Logenze
      2.0 mg
      4.0 mg
Transdermal patch
      15 mg/16h
      21.0 mg/24h (Novartis)
      21.0 mg/24h (Alza)
Oral solution 2.0 mg
Oral capsules 3-4 mg
Sublingual tablet 2.0 mg
Cmax (ng/mL)
25.9
38.9
12.5
  9.4
  8.1
8.6-10.5
  5.8
6-9
  4.4
10.8
11.9
17.0
21.9
  4.7
6-8
13.2
     Tmax
2.0 min
4.0 min
6 min
5 min
30 min
2.5-5 min
10 min
30 min
60 min
66 min
6.5 h
10 h
3.8 h
52 min
90 min
20 min
Ref.
(71)
(90)
(71)
(91)
(63)
(90)
(92)
(93)
(60)
(62)
(59)
(61)
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5.2. Deep lung delivery of nicotine
No DPI/MDI formulations for pulmonary delivery of 
nicotine have been approved yet for the management 
of nicotine addiction. Only two products, i.e., Nicotrol® 
and Nicorette® Inhalers (Pfizer) of nicotine are available 
as nicotine vapor inhaler; however, these devices deliver 
nicotine into buccal areas, not into the deep lungs, 
resulting in lowering plasma maximum concentration 
and delayed time to reach maximum concentration. In 
1997, Rose et al., patented a DPI formulation of nicotine 
bitartrate with lactose powders for lung delivery with a 
view to manage smoking cessation; however, no further 
details are accessible (67). In an early study, a nicotine 
pMDI formulation containing nicotine in ethanol with 
hydrofluoroalkane (HFA), produces a microaerosol of 
fine droplet size that mimics the nicotine delivered via 
tobacco smoke (68). The author emphasized the nicotine 
pMDI offered safer delivery compared to that of smoked 
tobacco where heat, carcinogens, and carbon monoxide 
produce various adverse effects. Delivery of nicotine 
to the deep lung was comparable to cigarette smoking 
and this method showed to reduce cravings and nicotine 
withdrawal symptoms (69). A breath-activated MDI 
nicotine formulation, that produced a fine particle dose 
(FPD) up to 60%, would rapidly produce maximum 
plasma concentration to reduce smoking urges (70). 
This type of nicotine delivery is encouraging and 
suitable for relieving nicotine addiction; however, no 
further details are available. Very recently, using a large 
spacer with MDI lung delivery of nicotine produced 
a median maximum plasma concentration, which was 
about 50% of the amount that was obtained by smoking 
a cigarette (71). This formulation produced higher peak 
plasma levels and was achieved rapidly compared to 
those of many current forms of nicotine replacement 
therapy. In addition, inhaled MDI formulation showed 
self-satisfaction and reduce urge to smoke similar 
to a cigarette. Gonda et al., delivered clean nicotine 
aqueous solution to the deep lung for tobacco smoking 
cessation treatment using a promising device, AERx 
Essence® inhaler (72,73) and produced a rapid and dose 
proportional increase in plasma nicotine concentration 
within 1 min (data not accessible). Although nicotine 
was eliminated rapidly from the blood stream, prolonged 
craving reduction was observed without administering 
another dose. The craving reduction could be due to 
changes in brain nicotinic receptor regulation and 
neuroadaptation associated with brain reward circuitry 
(3-5). These studies suggested that deep lung delivery 
of nicotine using inhaler devices with better formulation 
would be an effective way to eliminate the craving for 
cigarettes and other tobacco products.
 Nicotine absorption via lung from smoking is very 
rapid and currently available nicotine products (Table 
3) deliver nicotine more slowly compared to that of 
smoking, which indicates that the pulmonary delivery is 
advantageous over other routes. The typical steady-state 
plasma concentrations of nicotine from gum, inhaler, 
sublingual tablets, and nasal spray is in the range of 
5-15 ng/mL and from nicotine patches (according to 
the design and dose of nicotine in patches) in the range 
of 10-20 ng/mL (Table 3). Administration of nicotine 
capsules or solution found to produce peaks plasma 
concentrations in about 1 h (59,62). The absorption 
of nicotine from gum is not fast and frequent dosing 
is required to achieve good absorption from the oral 
mucosa to achieve peak plasma levels of nicotine. 
Nicotine absorption from transdermal patch is very 
slow and plasma concentration rises gradually over 
6-10 h (depending on the type of product). The nicotine 
absorption from nasal spray was rapid and peak plasma 
concentration achieved within 5 min after administration 
(63) with a high individual variability. Hence, from the 
table it is evident that pulmonary delivery confirmed 
promising outcome compared to those of currently 
available non-inhaled nicotine products (tablets, 
capsules, nasal spray, gums, etc.).
5.3. Non-nicotine based medications 
Currently there are some non-nicotine based drugs, 
such as bupropion (Zyban®) and varenicline (Chantix®) 
available for the treatment of nicotine addiction and 
these drugs are considered better for the management 
of smoking cessation (74-78). Bupropion was originally 
marketed as an antidepressant agent but the effect 
on nicotine addiction appears to be separate from 
its antidepressant effect. It is an inhibitor of brain 
dopamine uptake process. In addition, bupropion in 
low doses can block brain nAChR function (74). The 
blockade of nAChRs function could decrease positive 
reinforcement effects in addicted populations (75). This 
drug is extensively metabolized by liver enzyme (t1/2 
approximately 21 h). The prolonged absorption of this 
drug was observed from sustained release and extended 
release formulations, with Tmax values of 3.0 and 5.0 h, 
respectively compared to that of immediate release (Tmax 
1.5 h); however, Cmax and AUC values found to increase 
proportionately with dose for all of these formulation 
(76). It is important to note that the pharmacokinetic 
profile of this drug is affected by age, sex, smoking, 
and renal and liver of the consumers. This drug is 
administered as a sustained-release formulation because 
of the major adverse effect – generalized seizures, 
which follow up high peak plasma concentration of that 
drug. The commonly observed side effect of bupropion 
is insomnia, but its occurrence can be reduced by taking 
the medication earlier in the day. Apart from insomnia, 
the most frequent effects are mouth dryness and nausea. 
It is contraindicated in patients who are suffering from 
seizure disorders. The dose is usually 150 mg/day for 
the first 3 days and then 150 mg twice daily. Bupropion 
is useful either as a monotherapy or in combination 
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with NRT. Combination with NRT seems to be safe but 
there is a lack of studies demonstrating an increased 
long-term quit rate (3,4). Evidence suggests that 
bupropion blocks brain dopamine and/or norepinephrine 
transporters for its antidepressant effect (3). Recently, it 
was found that bupropion with a very low concentration 
may act as an antagonist at certain subtype of nicotinic 
receptors (3,5). Whether this pharmacological property 
of bupropion may account for smoking cessation 
effect remains to be confirmed. Although pulmonary 
delivery of this drug has not been studied yet, this 
mode of delivery system would be expected to be more 
efficacious in terms of better pharmacokinetic (PK) and 
pharmacodynamic (PD) profiles for a better therapeutic 
outcome and effectiveness in the management of 
nicotine addiction resulting in enhancing the quit rate.
 Varenicline, the latest drug included in the list of 
non-nicotine medication as a potential drug for the 
management of smoking cessation. The drug was 
developed as a cytisine derivative to increase oral 
bioavailability and improve brain penetration (77). 
Varenicline is a partial agonist at nAChRs with higher 
affinity for brain alpha4beta2 compared to other 
subtypes such as α7 (77). Preclinical and clinical 
research has shown that varenicline produces less of a 
response than that of nicotine (30 to 60%) that would 
counteract the low brain dopamine levels occurred 
in the absence of nicotine during smoking cessation 
attempts (78). Thus the drug removes symptoms of 
craving and withdrawal. Overall, varenicline acts like 
a functional antagonist, reducing nicotine-induced 
brain dopaminergic activation (3,4). Moreover, the 
efficacy of varenicline was found to be higher than 
that of bupropion in preclinical and clinical studies 
(4). Several side effects with varenicline, such as 
nausea, vomiting, and vivid dreams have been reported 
in addicted populations. There have been reports 
about depression, suicidal thoughts, suicides, and 
serious neuropsychiatric symptoms in patients taking 
varenicline with recommended dose (79). The dose is 
usually started at a dose of 0.5 mg once daily for the 
first 3 days, 0.5 mg twice daily for the next four days 
and than 1 mg twice daily. The half-life of this drug 
is approximately 17 (± 3) h after repeated dose, with 
Tmax 4.3 (± 2.3) h and Cmax 4.0 (± 0.7) ng/mL (80). 
Recommended duration of treatment is 12 weeks but in 
special groups of patients, who have had relapse with 
shorter duration of treatment, varenicline can be taken 
even for 24 weeks (4). No pulmonary delivery of this 
drug or PK of inhaled varenicline has been investigated 
so far. Despite some objections with reference to its 
use, varenicline is perceived by many clinicians and 
researchers as the effective smoking cessation aid. Like 
NRT and bupropion, lung drug delivery with better 
formulations of varenicline may be introduced for a 
better therapeutic outcome and effectiveness in the 
management of nicotine addiction. It is expected that 
the deep lung delivery of this drug would improve the 
PK/PD profiles for smoking cessation compared to 
those of existing delivery methods.
 The overall justification for the currently available 
pharmacotherapies for nicotine addiction is to mimic or 
replace the effects of nicotine by providing an agonist 
itself or to control the neurobiological mechanisms by 
NRT. However, these approaches do not show long 
lasting outcome. It has been reported that under an 
ideal circumstances the maximum abstinence rates are 
only 25 to 35% and approximately 80% of patients 
who used one of the currently available medications 
returned to smoking within the first year (81). Given 
the evidence, it is now comprehensible that there is a 
need to develop more effective therapy compared to 
those of currently available products for long lasting and 
effective cessation of tobacco smoking. The pulmonary 
route seems to be ideal for rapid delivery of nicotine in 
case of NRT or other medications to the brain, where it 
has its appropriate therapeutic effects. This route would 
allow quitters to absorb sufficient amounts of nicotine 
to diminish their smoking urges. Therefore, it would be 
excellent to develop such a product that can produce 
better PK/PD profiles following administration by 
inhalation. 
6. Summary
Tobacco smoking is strongly associated with an 
increased risk of developing coronary artery disease, 
chronic obstructive pulmonary disorder, and cancer 
(82). The odds of successful smoking cessation 
are improved with pharmacotherapy as reviewed 
above. These therapies are thought to work primarily 
by replacing nicotine (e.g. ,  NRT) or modestly 
stimulating or inhibiting nicotine effects in the brain 
(e.g., varenicline or bupropion), thereby minimizing 
withdrawal symptoms experienced during smoking 
cessation. While the role of effective pharmacotherapy 
is essential for effective management of nicotine 
addiction, better formulation with innovative drug 
delivery might advance therapeutic outcome for 
various disorders associated with tobacco addiction. 
It is expected that treatment of nicotine addiction will 
be improved with least side effects using proposed 
pulmonary drug delivery method in the coming years. 
However, insufficient data are available to rank-order 
the effectiveness of the different cessation agents that 
are currently on market. Selection of an effective active 
agent should be individually tailored for each patient. 
Important factors to consider include patient preference, 
medication compliance issues, previous experience 
with cessation agents, and patient characteristics, 
e.g., contraindications, history of depression, and 
level of smoking. Finally, pharmacotherapy should be 
accompanied by appropriate behavioral counseling to 
enhance long-term cessation rates.
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